Savella vs Cymbalta for Fibromyalgia: How They Compare, Side Effects and Non-Drug Options

If you are living with fibromyalgia and considering medication, two names come up repeatedly: Savella (milnacipran) and Cymbalta (duloxetine). Both belong to the same drug class, both carry FDA approval for fibromyalgia, and both aim to dial down pain by acting on brain chemistry. But they are not identical.

This article breaks down how Savella and Cymbalta compare on efficacy, side effects, and withdrawal risk. It also covers the non-drug approaches that major guidelines now recommend as first-line fibromyalgia treatment, and where behavioral pain programs fit into the picture.

Key Takeaways

• Cymbalta and Savella are both FDA-approved SNRIs for fibromyalgia, but Cymbalta is more serotonin-selective while Savella affects serotonin and norepinephrine more equally.
• Neither drug has demonstrated clear overall superiority, though Cymbalta may edge out Savella on pain and mood, while Savella may help more with fatigue.
• Both carry meaningful side effect and withdrawal risks, with trial discontinuation rates ranging from 12% to 26%.
• EULAR guidelines recommend non-drug approaches, including exercise and behavioral therapy, as first-line fibromyalgia treatment before adding medication.
• Lin Health's approach is based on behavioral and neuroplastic pain science, delivered through coach-led sessions and covered by most major insurance plans.

What Are Savella and Cymbalta?

Savella (milnacipran) and Cymbalta (duloxetine) are serotonin-norepinephrine reuptake inhibitors, or SNRIs. Both increase the availability of two neurotransmitters, serotonin and norepinephrine, in the brain and spinal cord.

The FDA approved Cymbalta for fibromyalgia in June 2008 and Savella in January 2009. A third drug, pregabalin (Lyrica), which works through a different mechanism, received approval in June 2007. These three remain the only FDA-approved fibromyalgia drugs.

Cymbalta also carries FDA approval for major depressive disorder, generalized anxiety disorder, diabetic peripheral neuropathy, and chronic musculoskeletal pain. Savella, by contrast, is approved only for fibromyalgia in the United States.

How SNRIs Work for Fibromyalgia

Fibromyalgia involves changes in how the nervous system processes pain. Research points to altered descending pain-inhibitory pathways, which normally act as the body's built-in pain-dampening system. In people with fibromyalgia, these pathways function less efficiently, allowing pain signals to amplify rather than fade.

Both serotonin and norepinephrine play roles in pain inhibition through these descending pathways. By blocking the reabsorption of these neurotransmitters, SNRIs aim to restore some of that natural pain-dampening activity.

The key difference between the two drugs is their selectivity:

• Cymbalta (duloxetine) inhibits serotonin reuptake roughly 10 times more than norepinephrine reuptake
• Savella (milnacipran) inhibits both at approximately equal ratios

In practice, this difference in binding ratios does not predict response for a given patient. Many clinicians try one SNRI first and switch to the other if the response is inadequate.

Savella vs Cymbalta: How They Compare on Efficacy

No large, head-to-head randomized trial has directly compared duloxetine and milnacipran for fibromyalgia. The available evidence comes from indirect comparisons and smaller studies.

Indirect comparisons across placebo-controlled trials show no significant efficacy difference for 30% pain relief or dropout rates due to adverse events. That same analysis suggested duloxetine may reduce pain more and improve sleep disturbance relative to milnacipran, while milnacipran may improve fatigue more than duloxetine.

In a six-month prospective follow-up of fibromyalgia patients, duloxetine showed larger pain reduction than milnacipran, though the study was small and patients were not randomly assigned to treatments.

On cost-effectiveness, duloxetine 120 mg and pregabalin 450 mg showed more favorable cost-effectiveness than amitriptyline, while milnacipran regimens did not in the same analysis.

Side Effects: Savella vs Cymbalta

Both medications share a side effect profile typical of SNRIs: nausea, constipation, dry mouth, and increased sweating. But they differ in their specific risk patterns, and those differences matter.

Savella Side Effects

Across pooled clinical trials, 23% to 26% discontinued Savella due to adverse reactions (23% on 100 mg/day, 26% on 200 mg/day). The most common side effects occurring at twice the placebo rate included:

• Nausea (reported by 34-38% of participants)
• Constipation
• Hot flashes
• Increased sweating
• Vomiting
• Elevated heart rate and blood pressure, a cardiovascular concern specific to Savella
• Palpitations

The FDA label specifically warns about heart rate and pressure increases, making Savella less suitable for patients with uncontrolled hypertension or significant cardiovascular risk.

Cymbalta Side Effects

In fibromyalgia trials, approximately 12% to 18% discontinued duloxetine due to adverse events, depending on dose. Common side effects include:

• Nausea (the most frequent early side effect)
• Dry mouth
• Constipation
• Somnolence and fatigue
• Decreased appetite
• Increased sweating
• Dizziness

A dose of 120 mg/day carries more side effects than 60 mg/day, without strong evidence of additional pain benefit. Most prescribers start at 60 mg/day.

Side-by-Side Comparison

Withdrawal and Discontinuation Risks

Both Savella and Cymbalta can cause withdrawal symptoms when stopped abruptly. The FDA prescribing information for both drugs recommends a gradual dose reduction rather than sudden discontinuation.

Withdrawal symptoms may include dizziness, nausea, headache, irritability, insomnia, and a sensation often described as "brain zaps." These symptoms typically begin within days of stopping the medication and may persist for several weeks.

Cymbalta has received particular attention for withdrawal difficulties. In clinical and post-marketing experience, symptoms may last months after discontinuation, even with a gradual taper. This is one reason many clinicians treat the decision to start Cymbalta as a meaningful commitment.

If you are considering stopping either medication, work with your prescriber to develop a taper plan. Reducing the dose in small increments over several weeks minimizes the risk of withdrawal symptoms.

Beyond Medication: Non-Drug Approaches for Fibromyalgia

Major clinical guidelines are clear on this point: non-drug therapy first-line for fibromyalgia, with medication added only when the initial approach is not enough. The revised EULAR recommendations gave exercise the only "strong for" rating among all fibromyalgia interventions, pharmacological or otherwise.

That framing is worth sitting with. Medications like Savella and Cymbalta can lower pain scores, but they address symptoms without directly targeting the altered central pain processing that drives fibromyalgia. Non-drug approaches, particularly behavioral therapies, work on the nervous system itself.

Exercise

Aerobic exercise and strength training improve pain and function in adults with fibromyalgia. EULAR rates exercise as the strongest evidence-based intervention available. Starting slowly and building gradually is critical, as overexertion can temporarily increase symptoms in this population.

Cognitive Behavioral Therapy (CBT)

CBT is the most studied behavioral therapy for fibromyalgia. It reduces pain intensity and improves sleep quality and quality of life in adults with this condition. For sleep specifically, CBT-I (cognitive behavioral therapy for insomnia) outperforms sleep medications in fibromyalgia, according to a 2025 systematic review published in Rheumatology. CBT approaches for pain address both the physical experience and the thought patterns that can amplify it.

Acceptance and Commitment Therapy (ACT)

ACT takes a different angle. Rather than challenging painful thoughts directly, ACT teaches psychological flexibility, helping people engage in valued activities even when pain is present. A meta-analysis found that ACT improves pain and mood for people with fibromyalgia, with digital delivery formats showing particularly strong adherence rates.

Emotional Awareness and Expression Therapy (EAET)

EAET is a newer therapy that targets the emotional roots of chronic pain. In 230 adults with fibromyalgia, EAET improved pain and functioning compared to fibromyalgia education, with roughly a third of participants reporting they were "much better" or "very much better."

Among older adults with chronic musculoskeletal pain, 63% achieved pain reduction with EAET, compared to 17% receiving CBT. Effects were sustained at six months. Lin Health summarizes the evidence for EAET in their clinical research library.

How Lin Health Helps with Fibromyalgia

Fibromyalgia is now widely understood as involving nervous system pain processing changes. The pain alarm, in effect, gets stuck. Tissues may be structurally healthy, but the nervous system continues sending danger signals, creating real and persistent pain that can spread and intensify over time. This concept, sometimes called nociplastic pain, sits at the center of modern fibromyalgia research.

Lin Health's approach is based on this understanding. Rather than masking pain with medication alone, the program uses behavioral and mind-body therapies to retrain the nervous system's pain response. Modalities include CBT, ACT, and emotional awareness techniques, all delivered through a structured program:

• Live coaching sessions with trained recovery coaches, weekly
• A guided app with learning modules and daily practice exercises
• Between-session support via chat with your assigned coach

What sets Lin Health apart from self-guided apps or general talk therapy is specialization and access. The program is designed specifically for conditions like fibromyalgia, not general mental health. And because Lin Health uses recovery coaches, the program is covered by most insurers with zero out-of-pocket cost for most patients. Wait times are short, often a same-day callback after signup.

You can explore the Lin Health fibromyalgia guide for a deeper look at the neuroscience, behavioral tools, and what to expect from the program. Recovery stories from patients who have completed the program are also available.

If medications like Savella or Cymbalta have not fully addressed your fibromyalgia symptoms, or if side effects have made them difficult to continue, behavioral approaches may be worth exploring alongside or instead of pharmacological treatment. Lin Health offers behavioral and lifestyle support for fibromyalgia, delivered by trained recovery coaches and covered by most insurance plans in CO, TX, FL, CA, and NY. Wait times are short, often a same-day call. Check your eligibility.

FAQ

Are Savella and Cymbalta the same type of medication?

Both are serotonin-norepinephrine reuptake inhibitors (SNRIs), but they differ in how strongly they affect each neurotransmitter. Cymbalta is more serotonin-selective, while Savella targets both neurotransmitters more evenly. This difference may influence which symptoms respond to each drug.

Which is better for fibromyalgia pain, Savella or Cymbalta?

Neither has shown clear overall superiority. Indirect comparisons suggest Cymbalta may have a slight edge on pain and mood, while Savella may help more with fatigue. Individual responses vary, and many patients try both before finding the right fit.

Can I take Savella and Cymbalta together?

No. Taking two SNRIs simultaneously increases the risk of serotonin syndrome, a potentially dangerous condition. A prescriber may switch you from one to the other with an appropriate washout period, but they should never be taken at the same time.

What are the most concerning side effects of Savella?

Elevated blood pressure and heart rate are the most notable risks specific to Savella. The FDA label carries a warning about these cardiovascular effects. Nausea is the most common reason patients discontinue the drug in clinical trials.

Is Cymbalta hard to stop taking?

Cymbalta can cause withdrawal symptoms including dizziness, nausea, and "brain zaps" when discontinued. A gradual taper under medical supervision reduces this risk. Some patients report withdrawal symptoms lasting weeks to months even with tapering.

Can you treat fibromyalgia without medication?

EULAR guidelines recommend non-drug approaches as first-line treatment for fibromyalgia. Exercise, CBT, ACT, and other behavioral therapies all have evidence supporting their use. Many patients manage fibromyalgia effectively by combining behavioral approaches with lifestyle changes, with or without medication.

Does insurance cover non-drug fibromyalgia treatment?

Coverage varies by plan and provider. Programs like Lin Health, which use coach-led behavioral approaches, are covered by most major insurance carriers in several US states with zero out-of-pocket cost. Traditional CBT may be covered under mental health benefits, though availability and wait times can be barriers.

What is the newest treatment approach for fibromyalgia?

Emotional awareness and expression therapy (EAET) is among the newest evidence-based behavioral approaches. In fibromyalgia and chronic musculoskeletal pain trials, EAET has shown advantages over education controls and, in some outcomes, over CBT. Programs like Lin Health incorporate these principles alongside CBT and ACT.

This article is for informational purposes and is not medical advice. Consult a qualified healthcare provider before starting, changing, or stopping any medication or treatment plan.

Reviewed by the Lin Health clinical team. Last reviewed: November 2026.